Kornimate/medical-research-clean huggingface dataset:
changes in coagulation in colorectal cancer patients undergoing surgical treatment

Conditions: Peritoneal Metastases; Peritoneal Carcinomatosis; Colorectal Neoplasms Malignant; Intestinal Neoplasms; Cytoreductive Surgery; Venous Thromboembolism; Bleeding; Laparoscopic Surgery; Coagulation; Surgical Procedures, Operative; Postoperative Complications; Laparoscopy; Minimally Invasive Surgical Procedures; Surgical Oncology

Summary: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (hipec) has prolonged the survival substantially for selected patients with peritoneal metastases from colorectal cancer.bleeding and thromboembolic disease have been reported as postoperative complications related to this advanced open surgical treatment. however, perioperative changes in coagulation and fibrinolysis are only sparsely reported in the literature.the mainstay of treatment with curative intend of none-advanced colorectal cancer is minimally invasive laparoscopic surgery followed by adjuvant chemotherapy. the approach is considered associated with a lower risk of thromboembolic disease than open surgery. despite differences in extent of surgery and thromboembolic risk the same extended thromboprophylaxis regimen for 28 days is currently prescribed to patients undergoing cytoreductive surgery with hipec as well as minimally invasive rectal cancer resection. this study aims to investigate all parts of the coagulation system and fibrinolysis, and thereby thromboembolic risk and potential bleeding in two groups of patients with different extent of surgical trauma: 1) colorectal cancer patients undergoing cytoreductive surgery with hipec and 2) rectal cancer patients undergoing minimal invasive rectal cancer resection. our hypothesis is that patients undergoing cytoreductive surgery with hipec are exposed to more aggravated alterations of coagulation and fibrinolysis than patients undergoing minimally invasive rectal cancer resection.


Eligibility criteria:
inclusion criteria: cytoreductive surgery with hipec patients: * able to give informed consent * age ≥ 18 years * diagnosed with peritoneal metastases from colorectal cancer * planned to undergo cytoreductive surgery with hipec minimally invasive rectal cancer patients: * able to give informed consent * age ≥ 18 years * diagnosed with rectal cancer * planned to undergo minimal invasive rectal cancer resection with one of: total mesorectal excision, partial mesorectal excision or abdominoperineal excision exclusion criteria (both groups): * thromboembolic event within 90 days before surgery * secondary malignancy within previous 5 years or concomitant, except non-melanoma skin cancer.

Keywords: bleeding venous thromboembolism coagulation cancer surgery thromboprophylaxis colorectal cancer cancer peritoneal metastases postoperative complications rectal cancer
internet-based program for prevention and early intervention of adolescent depression

Conditions: Depressive Symptoms

Summary: background: depression is prevalent and can have devastating effects on the life of adolescents. computerized intervention programs for depression have shown positive results. there is less evidence in prevention and early treatment for depression in latin american adolescents. purpose: the purpose of this study is to determine whether a stepped internet-based program is effective to prevent and early intervene depression in adolescents attending 9th to 11th grade in eight schools in santiago, chile. study design: a two-arm cluster-randomized clinical trial will be carried out with approximately 600 adolescents.


Eligibility criteria:
inclusion criteria: * attending from ninth grade to eleventh grade in the eight participating schools. * informed consent and informed assent. * score in the depression questionnaire phq-9 adolescent version between 5 and 14. exclusion criteria: * high suicide risk defined by score in question 9 of the phq-9 adolescent version of 2 or more. * current treatment with antidepressant drugs. * current treatment with psychotherapy.

Keywords: depression adolescence prevention early intervention internet-based
evaluation of ankle propriocement and stability

Conditions: Ankle Sprains; Instability, Joint

Summary: the objective of the study is to evaluate the postural control and proprioception before and after external capsulo-ligament reconstruction for ankle instability.

the objective of the study is to evaluate the postural control and proprioception before and after external capsulo-ligament reconstruction for ankle instability using differents tests, questionnaires and instrument: * delos system (computerized oscillating platform) * foot and ankle ability measure (faam), l'american orthopaedic foot and ankle score (aofas), sf12 questionnaires * modified star excursional balance test (msebt) and short physical performance battery (sppb)

Eligibility criteria:
inclusion criteria: * patients who must undergo surgery; * patients of both sexes aged between 18-40 years; * patients who have given their informed written consent to participate in the study; * patients who have given their consent to reach the hospital to perform the 4-month check-up exclusion criteria: * patients with bmi\> 30 kg / m2; * patients with rheumatoid arthritis; * patients with chronic inflammatory joint diseases; * patients with pre-existing abnormalities of the ambulatory kinematics (amputations, neuro-muscular diseases, polio, hip dysplasias); * patients with severe arthrosis of the ankle (kellgren-lawrence\> 3); * patients with severe knee arthritis (kellgren-lawrence\> 3); * patients with acl injury; * patients with severe postural instability; * patients with cognitive impairments; * patients with concomitant neurological diseases.

Keywords: sprain brostrom ankle instability
study of sensory deficits in the upper limb after stroke

Conditions: Stroke

Summary: the overall aim of the project is to gain insight in sensory deficits and recovery patterns in the upper limb post stroke and its association with brain lesion localisation. furthermore, the investigators will identify associations of deficits in sensory modalities with upper limb impairments, activities and participation at different time points after stroke. identification of the sensory deficits, along with further insights in their relation with objective neurophysiological and neuroanatomical measures will contribute to the amelioration of goal-setting for the rehabilitation of upper extremity function after stroke. these functions are indispensable during several daily activities as well in different sports and leisure activities. this project is an important step towards a better delineating of treatment interventions for the upper limb and to a better guiding of individual needs for post-stroke treatment in the future.


Eligibility criteria:
inclusion criteria: * first-ever stroke as defined by who * ≤ 5 days post stroke * motor impairment and/or a sensory impairment * ≥ 18 years old * sufficient cooperation to execute evaluations exclusion criteria: * other neurological impairments such as previous stroke, head injury or multiple sclerosis (these might affect sensory ability independently of the stroke) * stroke-like symptoms caused by subdural hematoma, tumour, encephalitis or trauma * no informed consent * pre-stroke barthel index \< 95 out of 100 points (to be able to distinguish between pre-existing disabilities and disabilities resulting from the stroke)
the effects of nicotinamide adenine dinucleotide (nad) on brain function and cognition

Conditions: Mild Cognitive Impairment; NAD

Summary: the purpose of this study is to determine the effects of niagen (nicotinamide riboside, vitamin b3), on nad levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (mci).

niagen is a patented formula which is the first and only commercially available form of nicotinamide riboside (nr). it has been proven in basic science studies as a highly effective nad booster, but it also works as a vitamin b3 supplement. nad helps pass energy from glucose to other pathways in the cell. niagen (nicotinamide riboside, vitamin b3) is one of the most effective nad+ precursors to support cellular health. the purpose of this study is to determine the effects of niagen (nicotinamide riboside, vitamin b3), on nad levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (mci).

Eligibility criteria:
inclusion criteria: * previously diagnosed with mci based on inclusion criteria of texas alzheimer's research care and consortium (tarcc) study (irb: hsc20090535h). we are enrolling both genders, all races and ethnic groups. * two week washout period for participants who were taking opioids or a dose of niacin over 200mg exclusion criteria: * previously considered as healthy individuals without a mci or alzheimer's disease diagnosis based on exclusion criteria of the tarcc study (irb: hsc20090535h). * neurological, psychiatric or active systemic medical disease * diabetes * moderate or severe depression and/or anxiety as determined the geriatric depression scale (gds) and the geriatric anxiety scale (gas), respectively * diagnosis of dementia * hearing, vision, motor or language deficits * alcohol or drug abuse * implantation of metal devices * administration of alzheimer's drugs, anticholinergics, neuroleptics, anticonvulsants, opiates, systemic steroids, and mood-stabilizers. * no opioid use while participating in study

Keywords: mild cognitive impairment mci nad nicotinamide riboside aging
impact of surgical technique on post-operative complications in urgency ostomy confection

Conditions: Colostomy Stoma; Colostomy Complication; Obstruction Bowel; Surgical Complication; Surgical Procedure, Unspecified

Summary: this is a single-center retrospective cohort study on cancer patients who underwent emergency ostomy. our objective was to compare the incidence of surgical complications as well as the length of hospital stay among three different techniques for ostomy confection (laparotomy, the conventional local approach, described as trephination, and laparoscopy).


Eligibility criteria:
inclusion criteria: * patients who underwent emergency colostomy or ileostomy exclusion criteria: * patients who underwent other major procedures at the time of the surgery, such as enterectomy, colectomy, or tumor or other organ resection

Keywords: colostomy laparoscopy ostomy
a comparison of dalteparin and tinzaparin for prevention of blood clots in hemodialysis patients on oral anticoagulants having surgery

Conditions: Thromboembolism; Hemodialysis

Summary: the purpose of this study is to better understand if either dalteparin or tinzaparin is a better drug to use in dialysis patients on blood thinners who are at high risk of developing blood clots and need surgery.

a prospective multicenter randomised trial involving 60 consecutive eligible and consenting patients from teaching hospitals in canada. patients will be randomised to either tinzaparin or dalteparin to investigate the pharmacokinetics of both low molecular weight heparins (lmwh) perioperatively in a special population, namely end stage renal disease (esrd) dialysis patients. to date although there exists evidence to suggest tinzaparin may be safe in patients on hemodialysis, lmwhs as a group have not been investigated in the perioperative setting in these patients. this protocol has been developed so that the pharmacokinetic behaviour of tinzaparin and dalteparin can be compared but also so that the duration off warfarin is minimised. therapeutic doses of lmwh are administered pre-procedure during as much time of the period as possible that oral anticoagulation is sub-therapeutic.

Eligibility criteria:
inclusion criteria: * informed consent * patients aged \>= 18 with end stage renal disease requiring chronic hemodialysis (hd) three times a week and clinically stable on hd for 4 weeks (x 4 wks) * patients requiring active oral anticoagulation for prosthetic heart valves, recent deep vein thrombosis \>= 1 month, or patients with atrial fibrillation and a major risk factor (previous transient ischemic attack \[tia\] or stroke, high blood pressure, diabetes, aged \>= 75, moderate/severe left ventricle dysfunction) who require elective non-cardiac surgery or an invasive procedure with reversal of their anticoagulant therapy. exclusion criteria: * evidence of active bleeding prior to stopping warfarin * hemoglobin \<= 90 or platelet count \<= 100x10\^9/l * uncontrolled hypertension or stroke within 6 months of study commencement * spinal or neurosurgery * eye surgery (excluding cataract surgery) * life expectancy less than 3 months * patients requiring cardiac surgery * presence of active duodenal ulcer

Keywords: prophylaxis thromboembolic disease end stage renal disease hemodialysis pharmacokinetics low molecular weight heparin innohep tinzaparin fragmin dalteparin anti xa inr oral anticoagulation warfarin coumadin
effect of adiponectin genetic polymorphism on rosiglitazone response

Conditions: Diabetes Mellitus

Summary: the aims of the present study were to investigate the association between adiponectin gene polymorphisms and the response to rosiglitazone monotherapy in t2d patients. a total of 255 t2d patients and 120 health volunteers were enrolled in this study. 42 t2d patients with -11377(c/g) or +45(t/g) genotypes were selected to administrate orally 4mg rosiglitazone daily for 12 consecutive weeks.

the aims of the present study were to investigate the association between adiponectin allele +45(t/g) and -11377(c/g) polymorphisms and the response to rosiglitazone monotherapy in t2d patients. a total of 255 t2d patients (138 males, 117 females) aged from 25 to 70 years (mean 48.6 ± 10.7 years) and 120 healthy controls (53 females, 67 males) aged from 25 to 70 years(mean 47.1 ± 11.0 years) were enrolled to participate in this study. physical examination, medical history and serum biochemical tests were performed to identify healthy or t2d subjects. the diagnosis criteria of t2d patients were made according to the world health organization in 1997 by fasting plasma glucose (fpg  7.0 mmol/l) and/or postprandial plasma glucose test (ppg  11.1 mmol/l). the inclusion criteria of all subjects were that subjects had the range of body mass index (bmi) from 18.5 to 30 kg/m2 and did not administrate any ppar agonists in the last 3 months. patients who were receiving insulin treatment, pregnant or lactating women, or with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, and kidney disease or liver disease were excluded from this study. table 1 showed the characteristic profiles of t2d patients and healthy controls. there were no statistical differences in the age, height, weight, and bmi value between t2d patients and healthy controls. all subjects were recruited from local residents in changsha city, hunan province, p. r. china. the study protocol was approved by the ethics committee of xiangya school of medicine, central south university and written informed consents were obtained before the start of this study. a total of 42 t2d patients (23 male, 19 female) were randomly selected to be only treated with 4mg rosiglitazone daily for 12 consecutive weeks without change in previous medications.

Eligibility criteria:
inclusion criteria: * the diagnosis criteria of t2d patients were made according to the world health organization in 1997 by fasting plasma glucose (fpg  7.0 mmol/l) and/or postprandial plasma glucose test (ppg  11.1 mmol/l) * the inclusion criteria of all subjects were that subjects had the range of body mass index (bmi) from 18.5 to 30 kg/square meter and did not administrate any ppar agonists in the last 3 months. exclusion criteria: * patients who were receiving insulin treatment, pregnant or lactating women, or with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, and kidney disease or liver disease were excluded from this study.

Keywords: pharmacodynamics insulin resistance therapy volunteer
a study of the safety, pharmacokinetics, and pharmacodynamics of mtrx1011a in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a phase i multicenter study that will be conducted in the united states and consists of a double-blind, placebo-controlled, sad stage, followed by a double-blind, placebo controlled mad stage. the study will be conducted in approximately 65 adult patients between 18 and 80 years old who have ra.


Eligibility criteria:
inclusion criteria: 1. sad stage * ra diagnosed according to the acr * for patients taking anti-rheumatic therapies, receipt of a stable regimen prior to randomization * previous treatment with biologic agents, including anti-tnf agents, permitted but discontinued for an appropriate washout period 2. mad stage (same as above with the addition of the following) * failure of at least one biologic agent, defined as lack of or loss of response or intolerance * active disease defined by swollen and tender count exclusion criteria: * significant systemic involvement of ra, including vasculitis, pulmonary fibrosis, or felty's syndrome * malignancy, or prior malignancy, other than non-melanoma skin cancer or cervical carcinoma in situ that has been resected * history of treatment with any t cell-directed therapy

Keywords: ra
stopbang as a screening tool for obstructive sleep apnoea in pregnancy

Conditions: Obstructive Sleep Apnoea; Pregnancy

Summary: this study evaluates the use of the stopbang questionnaire to predict whether a pregnant woman with class iii obesity has obstructive sleep apnoea. all participants will have a stopbang score and modified stopbang score (substituting epworth score \> 10 with the tired item) calculated and then be tested with overnight pulse oximetry to see if they meet odi criteria for obstructive sleep apnoea.

obstructive sleep apnoea (osa) is a condition in which the muscles and soft tissues of the throat collapse during sleep, resulting in them stopping breathing for a short period. it affects around 4% of all pregnant women and is more common in obese people. pregnant women with untreated osa are more likely to have pregnancy complications and are more likely to need a caesarean section. babies born to mothers with untreated osa are more likely to need neonatal treatment. if osa is diagnosed and treated then these risks are reduced. in non-pregnant patients presenting for surgery, an screening tool called stopbang has been proven to be effective in identifying patients with osa. s: do you snore loudly? t: do you often feel tired during daytime? o: has anyone observed you stop breathing during your sleep? p: do you have high blood pressure? b: is your bmi \>35 kg/m2? a: are you \>50 years old? n: is your neck circumference \>40cm? g: is your gender male? the investigators aim to assess whether stopbang can be used to identify osa in obese pregnant women. the aim is to recruit 100 pregnant women with a body mass index (bmi) ≥40 at sunderland royal hospital. data will be collected when they attend for their anomaly scan or glucose tolerance test (during the second trimester of pregnancy). participants will complete an epworth sleepiness scale questionnaire and the stop questions before having their bmi, age and neck circumference documented. a stopbang score and modified stopbang score (substitute tired question with epworth \>10) will be calculated. all participants will then take a rad8 pulse oximeter home to record their overnight pulse rate and oxygen saturations. the oximetry results will be analysed by a respiratory physiologist and the oxygen desaturation index will be calculated. a statistician will analyse the results to determine if there is a relationship between stopbang score or modified stopbang score and likelihood of the pregnant women having osa. in a secondary analysis we will then see if any individual elements of stopbang can be used to predict osa.

Eligibility criteria:
inclusion criteria: * pregnant women * body mass index ≥ 40 at first midwife appointment * women ≥ 18 years of age exclusion criteria: * pre-existing obstructive sleep apnoea on treatment * pre-existing restrictive or obstructive respiratory disease * women with another cause of sleep apnoea (e.g. central sleep apnoea) * women under 18 years of age * women who do not provide or refuse consent * women lacking capacity to consent
biomarker role in assessing imaging needs for mild cranial trauma

Conditions: Brain Injuries; Head Injury

Summary: this study aims to determine whether a blood test can help doctors decide when to use a head ct scan for patients with a mild head injury. researchers are investigating whether the results from this blood test can aid in making better decisions about patient care and potentially reduce the need for imaging. in this study, researchers will collect blood samples to assess whether this specific blood test can help doctors decide when head imaging is necessary following a head injury. the goal is to determine whether the use of this test can reduce the number of head imaging procedures performed in the emergency department (ed).

the biomarker role in assessing imaging needs for mild cranial trauma (brain-ct) study aims to determine whether immediate access to blood biomarker data can help doctors decide when a ct scan is necessary for patients with mild traumatic brain injury (mtbi). the study will also explore how biomarker data influences clinical outcomes, such as hospital stay duration, costs, and recovery. additionally, it will identify specific patient groups where biomarker results may alter imaging decisions, assess the ability of biomarkers to predict worsening symptoms and develop predictive models to improve the accuracy of these tests compared to ct scans. the study will enroll adults presenting with suspected mild traumatic brain injury (mtbi) in the emergency department at grady memorial hospital. minors, pregnant individuals, wards of the state, prisoners, and those with cognitive impairments will not be enrolled. participants will undergo blood-based biomarker testing upon ed presentation. healthcare providers will be randomly assigned to either be blinded to the biomarker results or receive the results to guide their decision on ordering head ct imaging.

Eligibility criteria:
inclusion criteria: * adults aged 18-65 years old * mild tbi, defined as glasgow coma scale (gcs) score 13-15, presenting within 24 hours of injury * no prior head imaging for the same incident * presenting within 24 hours of onset of injury exclusion criteria: * patients with penetrating head injury * history of known brain abnormality including tumor, cerebrovascular malformation, recent brain surgery (within 6 months), prior head injury (within 6 months) * need for emergent surgical intervention for brain or alternate body organ injury * need for emergent bedside procedures for hemodynamic or orthopedic stabilization * patients deemed at higher risk for decline by the provider prohibit the 15-minute delay in obtaining imaging needed for biomarker testing.

Keywords: biomarkers brain imaging brain trauma head ct scan mild traumatic brain injury (mtbi)